Kirkham Young Ltd.
7 Watch Oak Business Centre, Chain Lane, Battle, East Sussex TN33 0GB

+44 (0)1424 777745
+44 (0)1424 777746

Artios Pharma completes £65m Series B financing

Global healthcare and life science company, Arix Bioscience plc announced today that its leading DNA Damage Response (DDR) company, Group Business Artios Pharma Limited has completed a £65 million Series B financing.

Significantly oversubscribed, the financing was led by Andera Partners and LSP (Life Sciences Partners), with participation from new investors Pfizer Ventures and Novartis Venture Fund (NVF).

The new funds will be used to advance Artios’ portfolio of small molecule DDR programmes, including targeting DNA polymerase theta, through clinical proof of concept trials.

Joe Anderson, Chief Executive Officer of Arix Bioscience plc commented: “Artios is actively developing a pipeline of highly promising, first-in-class DDR therapies which have the potential to bring real impact to cancer patients.

“As early investors in Artios, we are excited to continue working with the team and this group of renowned investors to build a world leading DDR company and create significant value for both patients and investors.”

Following this funding, Arix Bioscience will become the largest shareholder in Artios, taking 12.4 per cent of the total.

Niall Martin, Chief Executive Officer of Artios added: “Arix is focused on supporting innovation and creating and building world class companies. They were instrumental in putting together this stellar investor syndicate and we value their continued support as we progress the development of our novel DDR programmes.”

Artios actively develops a pipeline of therapies identified by global researchers in the DDR field, including Cancer Research UK.

Latest Jobs